A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.
Phase 1
Active, not recruiting
- Conditions
- Alzheimer Disease
- Interventions
- Registration Number
- NCT05345509
- Lead Sponsor
- Inventage Lab., Inc.
- Brief Summary
A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003
- Detailed Description
A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
- Healthy male or female, ≥18 and ≤55 years of age, non-smokers or occasional smokers (defined as smoking less than 10 cigarettes or nicotine equivalent per week, and willing to abstain from smoking during confinement at the study site).
- Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 and body weight ≥55.0 kg for males and ≥50.0 kg for females.
- Male subjects who are sexually active with a same-sex partner must be willing to use a condom until study exit.
- Male and female subjects who practice abstinence from sexual intercourse as a usual and preferred lifestyle.
- Willing to abstain from use of non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, aspirin, meloxicam, etc. from screening until study exit.
- Willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any protocol specific study procedures.
Exclusion Criteria
- Any clinically significant abnormal finding at physical examination at screening.
- Clinically significant abnormal laboratory test results or positive serology test results for human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus at screening.
- Positive pregnancy test at screening or Day -1 or lactating female subject.
- Positive drug or alcohol screen at screening or Day -1.
- Any history of malignancy or neoplastic disease.
- History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction, hypersensitivity, angioedema) to donepezil, piperidine derivatives, dimenhydrinate or derivatives, benzatropine or derivatives, or other related drugs, or to any excipient present in the formulation for any study drug.
- Presence of hereditary disorders including galactose intolerance, lactase deficiency, and glucose-galactose malabsorption (for Part B only).
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin >1.5x the upper limit of normal (ULN) at screening or Day -1.
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 as calculated by the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -1.
- Clinically significant ECG abnormalities (QTc >450 ms or PR interval >220 ms) or vital sign abnormalities (systolic blood pressure <90 or >140 mmHg, diastolic blood pressure <40 or >90 mmHg, or heart rate <50 or >100 bpm) at screening or Day 1.
- History of significant bradycardia or atrioventricular (AV) block.
- History of significant asthma (except for fully resolved childhood asthma) or chronic obstructive pulmonary disease (COPD).
- History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%).
- History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 month, or use of codeine within 3 months prior to screening.
- Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 30 days prior to dosing.
- Consumption of high levels of caffeine (equivalent to 3 regular cups of coffee or 2 energy drinks, per day).
- Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Aricept Tablet Aricept Tablet Aricept Tablet, QD, PO IVL3003 (A mg) IVL3003 SC, Single Dose IVL3003 (B mg) IVL3003 SC, Single Dose IVL3003 (C mg) IVL3003 SC, Single Dose IVL3003 (Dmg) IVL3003 Intramuscular IVL3003 (Emg) IVL3003 Intramuscular
- Primary Outcome Measures
Name Time Method AUCinf of Aricept Pre-dose, up to 1month Area under the concentration-time curve from time zero to infinity
AUClast of IVL3003 Pre-dose, up to 1month Area under the concentration-time curve from time zero to last
AUCinf of IVL3003 Pre-dose, up to 1month Area under the concentration-time curve from time zero to infinity
AUClast of Aricept Pre-dose, up to 1month Area under the concentration-time curve from time zero to last
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Nucleus Network
🇦🇺Melbourne, Australia